Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

Outcome

Stopped earlyThe sponsor has changed the development plans which is not for safety reasons. (Business decision)

Phase

Phase 1

Status

Withdrawn

Study type

Interventional

Start

1 September 2026

Expected end

1 June 2029

Enrollment

0 participants

Sites

0

Primary outcomes

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs); Clinically important changes in laboratory tests and vital signs

Sponsor

Industry

Results posted

No

Last update

28 August 2026

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.